Ranitidine Market Withdrawal
On April 1, the FDA requested the immediate withdrawal of all prescription and OTC ranitidine drugs due to NDMA contamination. NDMA levels in some ranitidine products has been found to increase with time and when stored at higher than room temperature, exposing consumers to unacceptable levels of NDMA.
Ranitidine products which includes tablets, capsules, and liquids will not be available to use for new or refills of prescriptions or OTC use. The table below provides a list of alternative therapies on the CareOregon formularies.
| Medicaid | CareOregon Advantage (Medicare) |
H2-receptor antagonists | Famotidine
Cimetidine
| Famotidine
Cimetidine
|
Proton Pump Inhibitors | Omeprazole
| Omeprazole
Pantoprazole 20mg, 40mg DR tablet Lansoprazole
Esomeprazole 20mg, 40mg DR capsule (ST Required) Rabeprazole 20mg tablet |
CareOregon has notified members who are affected by the withdrawal. This notice provides information about the withdrawal, alternatives available, and steps to dispose of the drug.
If you have questions about the withdrawal, call us at 503-416-4100 or 800-224-4840, Monday-Friday, 8 a.m. – 5 p.m. Option 3 for Provider, then Option 2 for Pharmacy Staff. After business hours, call 866-325-7344.
